25 results about "Negative symptom" patented technology

The present invention discloses a rehabilitation training evaluation system for schizophrenia patients, which relates to the field of data processing technology. The evaluation system includes a multimodal perception module, an edge intelligent processing module, and a dynamic graph network evaluation module. The technical key points are: integrating neurophysiology, behavioral trajectories, cognitive functions and environmental parameters to form a full-dimensional evaluation network of "micro-neural activity-meso-behavioral performance-macro-environment interaction". For example, it can simultaneously capture the implicit decoupling phenomenon of "reduced brain oxygen metabolism but normal autonomic nervous function" in patients with negative symptoms, avoiding the missed diagnosis of complex pathological mechanisms by traditional scales. Secondly, through the dynamic graph network, the synergy and causality of data of different dimensions are quantified, revealing the dynamic association path of "insufficient prefrontal cortex activation → social attention distraction → increased cognitive task error rate", providing a visual basis for mechanism research and intervention target selection.

A method is provided to bring about the necessary improvement in the user's empirical negative symptoms of schizophrenia. The calculation system can obtain a first metric associated with the user from multiple point in time. The calculation system can repeat the operation of identifying a configuration file selected based on the endpoint for improving empirical negative symptoms from multiple point in time. The calculation system can repeatedly present a set of content items identified by the configuration file to encourage the user to perform activities toward achieving the endpoint. The calculation system can obtain a second metric associated with the user from multiple point in time. If the second metric is lower than the first metric, the user is considered to have improved in the empirical negative symptoms of schizophrenia. The calculation system can enhance the effectiveness of medications the user is taking to cope with schizophrenia.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful as muscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

The present application relates to the use of roluperidone, i.e., Compound (I):and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.

The present invention relates to a compound for use in the treatment of schizophrenia, also known as CF3CN and referred to herein as the compound of formula I, 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazole-8-yl)benzonitrile. Preferably, the treatment of schizophrenia is the treatment of one or more symptom categories of schizophrenia. More preferably, the treatment is for the negative symptoms of schizophrenia. Alternatively, the treatment is for the cognitive symptoms of schizophrenia.

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention relates to the field of biomedicine, and discloses application of methionine in preparation of a medicine or a composition for improving social dysfunction caused by schizophrenia. Animal experiment results show that methionine can significantly improve the social novelty recognition ability of schizophrenia model mice by adjusting methylation. The medicine is preferably an oral preparation and can also be combined with vitamin B12, folic acid and other related auxiliary factors for use. According to the invention, the potential treatment value of methionine on the negative symptoms of schizophrenia is disclosed for the first time, and a new direction is provided for developing novel mental disorder intervention medicines or nutritional compositions.

This description relates to gastro-resistant controlled-release dosage forms comprising Compound (I): (see Formula) (I), or a pharmaceutically acceptable salt and / or solvate thereof, the pharmacokinetic properties of these dosage forms, and their preparation. The novel dosage forms described herein are useful for reducing the risk of QT prolongation in a subject and for treating a disorder in a subject in need, e.g., a subject diagnosed with schizophrenia, for example, in the treatment of negative symptoms in a subject diagnosed with schizophrenia who has the CYP2D6 EM genotype.

The invention relates to a novel compound as a 5-HT2A receptor inverse agonist, and a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for treating 5-HT2A receptor related diseases, wherein the diseases comprise non-motor symptoms caused by Parkinson's disease, such as delusional disorder, hallusion, depression, anxiety, cognitive disorder and sleep disorder; dementia-related mental disorders; major depression; or negative symptoms of schizophrenia and the like.

The invention relates to a combination comprising an effective amount of varenicline, or a salt thereof, and an effective amount of a glycine transport (GlyT) inhibitor. This combination achieves a selective dopamine increase in ventral striatum (nucleus accumbens) whilst not significantly altering dorsal striatum (associative striatum) dopamine. Such a selective dopamine elevation is of benefit for subjects suffering from schizophrenia. In particular, the combination of varenicline, or the salt thereof, and the GlyT transporter is useful for treatment of the negative symptoms in schizophrenia, without the risk of exacerbating the positive symptoms.

The present invention relates to novel compounds of Formula (I'), wherein P, Q, A, B, m, n, R1, R2, R9, R10, R11 and R12 are defined as in Formula (I'). These compounds may be useful asmuscarinic M4 receptor subtype ("M4-mAChR") positive allosteric modulators which are useful for the treatment or prevention of neurological and psychiatric disorders associated with muscarinic M4 receptor dysfunction and diseases in which the M4 receptor is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes of preparing such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders modulated by M4 muscarinic receptors.

Provided in the present invention is a novel use of Pynegabine as represented by formula (I) in the preparation of drugs for treating or preventing psychiatric disorders such as depression and schizophrenia. The present invention shows that Pynegabine can exhibit a significant antidepressant effect in an acute forced swimming mouse model and a chronic social defeat stress mouse model; additionally, Pynegabine also has a significant alleviation effect on both positive and negative symptoms in an MK-801-induced mouse model of schizophrenia. The present invention shows good development and application prospects.

The present invention relates to the compound 4-(6-oxo-2-(trifluoromethyl)-3, 6-dihydrochromene [7, 8-d] imidazol-8-yl) benzonitrile, also referred to as CF3CN, referred to herein as a compound of formula I, for use in the treatment of schizophrenia. Preferably, treatment of schizophrenia is treatment of one or more symptom classes of schizophrenia. More preferably, the treatment is directed against negative symptoms of schizophrenia. Alternatively, the treatment is directed against cognitive symptoms of schizophrenia.

The present invention relates to the use of (4-benzylpiperazine-1-yl)-[2-(3-methylbutylamino) pyridin-3-yl] methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a mental disorder of depressive symptom protrusion in a selected patient exhibiting learning and / or memory impairment, the psychiatric disorders include major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g., negative symptoms). The invention also relates to the use of NSI-189, or a pharmaceutically acceptable salt thereof, in the treatment of psychiatric disorders of depressive symptoms, including major depressive disorder (MDD), in selected patients exhibiting impaired learning and / or memory or certain EEG characteristics.

The present invention relates to the treatment of psychiatric or neurological disorders in patients in need of pleasant sensation (lack of pleasure or pursuit of incentive activities) by administering idarsone or a pharmaceutically acceptable salt thereof as a monotherapy or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorders include major depressive disorder, bipolar depression (such as bipolar type I or bipolar type II disorder), post-traumatic stress disorder, substance use disorder, pleasant sensation loss related aspects of schizophrenia (e.g., negative symptoms), and split affective disorder (e.g., with emotional and / or negative symptoms).

Provided herein are methods of ameliorating experiential negative symptoms of schizophrenia in a user in need thereof. A computing system may obtain a first metric associated with the user prior to a plurality of time instances. The computing system may repeat across a plurality of time instances, identifying a configuration file selected based on an endpoint for ameliorating the experiential negative symptoms. The computing system may repeat presenting the set of content items identified by the configuration file to prompt the user to perform the activity towards achieving the endpoint. The computing system may obtain a second metric associated with the user after the plurality of time instances. The user may show amelioration of experiential negative symptoms of schizophrenia, when the second metric is lower than the first metric. The computing system may increase the efficacy of the medication that the user is taking to address the schizophrenia.

To provide gastro-resistant, controlled release dosage forms and methods for preparing the same, the dosage forms being useful in reducing the risk of QT prolongation in a subject, in treating a disorder in a subject in need thereof such as a subject diagnosed with schizophrenia, and in treating negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.SOLUTION: A gastro-resistant, controlled release dosage form is provided comprising: i. about 4 mg to about 100 mg of a compound (I), or an equivalent amount of a pharmaceutically acceptable salt and / or solvate thereof; and ii. at least one controlled release agent. Compound (I).SELECTED DRAWING: None

The present disclosure provides a compound of Formula I: # imgabs0 # or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; the present disclosure provides processes for preparing such compounds, N-oxides, or salts; intermediates useful for the preparation of such compounds, N-oxides, or salts; the present invention relates to compounds, N-oxides, or salts, and compositions containing such compounds, N-oxides, or salts, and their use for the treatment of M4-mediated (or M4-related) disorders, including, for example, Alzheimer's disease, Parkinson's disease, schizophrenia (e.g., their cognitive and negative symptoms), pain, addiction, and sleep disorders.

The invention discloses application of lingenamine in preparation of a medicine for treating schizophrenia, and belongs to the technical field of biological medicine. By antagonizing 5-HT2AR and D2R receptors, the lingenamine can improve positive symptoms and negative symptoms of schizophrenia patients at the same time, and the defect that the curative effect of an existing medicine on the negative symptoms is limited is overcome. Meanwhile, adverse reactions such as over-sedation cannot be caused in the treatment process, side effects such as extrapyramidal system symptoms are avoided, and the treatment safety is remarkably improved. The lingenamine and the salts thereof have a definite multi-target action mechanism, and a new choice is provided for the treatment of schizophrenia. In addition, the medicine can be prepared into various dosage forms such as tablets, sustained-release preparations and injections, individualized administration is facilitated clinically according to specific conditions of patients, the medication scheme is flexibly adjusted, and therefore the flexibility and effectiveness of treatment are improved.

The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic α4-β2 and / or α7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).

The present application provides a new use of pirenzepine in the preparation of a drug for treating or preventing mental diseases such as depression and schizophrenia. The present application shows that pirenzepine can exhibit a significant antidepressant effect in a mouse acute forced swimming model and a chronic social defeat stress model, and can significantly alleviate the positive and negative symptoms of an MK-801 induced schizophrenia mouse model. It has a good development and application prospect.

The invention discloses application of echinacoside in treatment of schizophrenia. The method belongs to the field of medicines and comprises the following operation steps: screening schizophrenia risk genes; constructing a gene editing mouse model; evaluating a behavior normal form; predicting a protein structure; molecular docking; and carrying out behavioral pharmacology experiments. According to the echinacoside disclosed by the invention, in schizophrenia treatment, a healthy control mouse model and a schizophrenia mouse model are respectively subjected to intraperitoneal injection drug treatment for two weeks, and then the influence of echinacoside treatment on the schizophrenia mouse behavior phenotype is evaluated through a behavioral experiment. The pharmaceutical composition disclosed by the invention has a good treatment effect in the aspects of negative symptoms of schizophrenia, cognitive impairment and sensory gating defect, and a new drug target and a new treatment approach are provided for the treatment of schizophrenia.